Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib in Primary or Recurrent Dermatofibrosarcoma Protuberans
NCT00122473Phase 2Completed
- Sponsor
- Dermatologic Cooperative Oncology Group
- Start
- Jan 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in dermatofibrosarcoma protuberans (DFSP), sponsored by Dermatologic Cooperative Oncology Group. Primary endpoint: Tumor response at 12 weeks. Started Jan 2004; status: completed.
02
Drugs
03
Conditions
dermatofibrosarcoma protuberans (DFSP)
Beyond the preview
Go deeper on NCT00122473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00122473.